pepstatin has been researched along with Malaria--Falciparum* in 4 studies
4 other study(ies) available for pepstatin and Malaria--Falciparum
Article | Year |
---|---|
Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte.
During their intraerythrocytic development, malaria parasites export hundreds of proteins to remodel their host cell. Nutrient acquisition, cytoadherence and antigenic variation are among the key virulence functions effected by this erythrocyte takeover. Proteins destined for export are synthesized in the endoplasmic reticulum (ER) and cleaved at a conserved (PEXEL) motif, which allows translocation into the host cell via an ATP-driven translocon called the PTEX complex. We report that plasmepsin V, an ER aspartic protease with distant homology to the mammalian processing enzyme BACE, recognizes the PEXEL motif and cleaves it at the correct site. This enzyme is essential for parasite viability and ER residence is essential for its function. We propose that plasmepsin V is the PEXEL protease and is an attractive enzyme for antimalarial drug development. Topics: Amino Acid Motifs; Animals; Antimalarials; Aspartic Acid Endopeptidases; Biocatalysis; Endoplasmic Reticulum; Erythrocytes; Genes, Dominant; Genes, Essential; HIV Protease Inhibitors; Humans; Malaria, Falciparum; Multiprotein Complexes; Pepstatins; Phenotype; Plasmids; Plasmodium falciparum; Protein Binding; Protein Sorting Signals; Protein Structure, Tertiary; Protein Transport; Proteomics; Protozoan Proteins; Substrate Specificity | 2010 |
Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.
Cysteine protease inhibitors kill malaria parasites and are being pursued for development as antimalarial agents. Because they have multiple targets within bloodstream-stage parasites, workers have assumed that resistance to these inhibitors would not be acquired easily. In the present study, we used in vitro selection to generate a parasite resistant to growth inhibition by leupeptin, a broad-profile cysteine and serine protease inhibitor. Resistance was not associated with upregulation of cysteine protease activity, reduced leupeptin sensitivity of this activity, or expression level changes for putative cysteine or serine proteases in the parasite genome. Instead, it was associated with marked changes in the plasmodial surface anion channel (PSAC), an ion channel on infected erythrocytes that functions in nutrient and bulky organic solute uptake. Osmotic fragility measurements, electrophysiological recordings, and leupeptin uptake studies revealed selective reductions in organic solute permeability via PSAC, altered single-channel gating, and reduced inhibitor affinity. These changes yielded significantly reduced leupeptin uptake and could fully account for the acquired resistance. PSAC represents a novel route for the uptake of bulky hydrophilic compounds acting against intraerythrocytic parasite targets. Drug development based on such compounds should proceed cautiously in light of possible resistance development though the selection of PSAC mutants. Topics: Animals; Antimalarials; Biological Transport, Active; Cell Membrane Permeability; Cysteine Proteinase Inhibitors; Drug Resistance; Erythrocytes; Genes, Protozoan; Humans; In Vitro Techniques; Ion Channels; Leupeptins; Malaria, Falciparum; Plasmodium falciparum; Protozoan Proteins | 2008 |
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
The antimalarial activity of several antiretroviral protease inhibitor combinations was investigated. Data demonstrate that ritonavir and saquinavir behave synergistically with chloroquine and mefloquine. These data, and interactions with pepstatin-A, E-64, and bestatin, suggest that human immunodeficiency virus protease inhibitors do not target digestive-vacuole plasmepsins. Topics: Animals; Antimalarials; Chloroquine; Drug Synergism; HIV Protease Inhibitors; Humans; Malaria, Falciparum; Mefloquine; Parasitic Sensitivity Tests; Plasmodium falciparum; Ritonavir; Saquinavir | 2007 |
Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum.
During the erythrocytic stage of its life cycle, the human malaria parasite Plasmodium falciparum catabolizes large quantities of host-cell hemoglobin in an acidic organelle, the food vacuole. A current model for the catabolism of globin-derived oligopeptides invokes peptide transport out of the food vacuole followed by hydrolysis to amino acids by cytosolic aminopeptidases. To test this model, we have examined the roles of four parasite aminopeptidases during the erythrocytic cycle. Localization of tagged aminopeptidases, coupled with biochemical analysis of enriched food vacuoles, revealed the presence of amino acid-generating pathways in the food vacuole as well as the cytosol. Based on the localization data and in vitro assays, we propose a specific role for one of the plasmodial enzymes, aminopeptidase P, in the catabolism of proline-containing peptides in both the vacuole and the cytosol. We establish an apparent requirement for three of the four aminopeptidases (including the two food vacuole enzymes) for efficient parasite proliferation. To gain insight into the impact of aminopeptidase inhibition on parasite development, we examined the effect of the presence of amino acids in the culture medium of the parasite on the toxicity of the aminopeptidase inhibitor bestatin. The ability of bestatin to block parasite replication was only slightly affected when 19 of 20 amino acids were withdrawn from the medium, indicating that exogenous amino acids cannot compensate for the loss of aminopeptidase activity. Together, these results support the development of aminopeptidase inhibitors as novel chemotherapeutics directed against malaria. Topics: Amino Acids; Aminopeptidases; Animals; Cell Proliferation; Cytoplasm; Hemoglobins; Humans; Hydrolysis; Leucine; Malaria, Falciparum; Plasmodium falciparum; Protease Inhibitors; Protozoan Proteins; Vacuoles | 2007 |